Touchlight extends funding round to boost DNA vector manufacture
UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 976 entries already.
UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.
The Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.
EuropaBio has responded to the European Commissions public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
Cardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Visus Therapeutics has baged a 20m stock financing to advance development of Brimochol for presbyopia
British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Belgian semiconductor specialist Spectricity BV has baged 14m to speed up the development of mobile hyperspectral sensors for medical applications.
Life sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.